Use of Nimodipine in Aneurysmal Subarachnoid Hemorrhage

Clinical Use and Evidence

• The American Heart Association/American Stroke Association strongly recommends continued enteral administration of nimodipine at 60 mg 6 times a day to prevent delayed cerebral ischemia (DCI) and improve functional outcome in patients with aneurysmal subarachnoid hemorrhage 1
• Nimodipine's benefit appears to be through neuroprotection rather than preventing angiographic vasospasm, as it has not demonstrated a reduction in angiographic vasospasm despite improving clinical outcomes in patients with aneurysmal subarachnoid hemorrhage 2, 1
• A meta-analysis of 16 trials involving 3361 patients confirmed nimodipine's benefit in preventing DCI and improving functional outcomes in patients with aneurysmal subarachnoid hemorrhage 1
• Disruption of nimodipine therapy is associated with a greater incidence of DCI, highlighting the importance of consistent administration in patients with aneurysmal subarachnoid hemorrhage 1
• Maintenance of euvolemia (not hypervolemia) is recommended alongside nimodipine therapy to prevent DCI and improve outcomes in patients with aneurysmal subarachnoid hemorrhage 1

Alternative Indications and Administration Routes

• Unlike its use in aSAH, nimodipine has shown negative results when tested for treatment of acute ischemic stroke, with worse outcomes among patients treated with nimodipine than among control subjects, presumably due to its antihypertensive effects 3, 4, 5, 6, 7
• There are limited data to make any recommendation for intravenous or intra-arterial routes of nimodipine administration 1

Management of Subarachnoid Hemorrhage with Nimodipine and Amlodipine

Introduction to Nimodipine Therapy

• The American Heart Association recommends combining nimodipine with vasopressors, such as norepinephrine, in patients after aneurysm occlusion to counteract blood pressure lowering effects 8
• Temporarily reducing or holding amlodipine during the acute 21-day nimodipine treatment period is recommended, as controlling SAH complications takes priority over chronic hypertension management 8

Blood Pressure Management

• After aneurysm is secured, blood pressure targets shift—systolic BP peaks >150 mmHg increase rebleeding risk before obliteration, but maintaining cerebral perfusion becomes critical afterward 9, 8
• Alpha- and beta-adrenoreceptor blockers, such as labetalol, appear to have better outcomes with intensive blood pressure lowering compared to calcium channel blockers, renin-angiotensin system blockers, or nitrates in the setting of intracranial hemorrhage 9, 8